Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT – sham controlled trial
Arch. Clin. Psychiatry (Impr.)
;
44(2): 45-50, Mar.-Apr. 2017. tab, graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-845837
ABSTRACT
Abstract Background Thirty percent of schizophrenia patients are treatment-resistant. Objective This is a single-blinded sham-controlled trial to assess the efficacy of electroconvulsive therapy (ECT) as augmentation strategy in patients with clozapine-resistant schizophrenia. Methods Twenty three subjects were randomly assigned to 12 sessions of ECT (N = 13) or placebo (Sham ECT) (N = 10). The primary outcome was improvement on psychotic symptoms as measured by the mean reduction of the PANSS positive subscale. The assessments were performed by blind raters. Results At baseline both groups were similar, except for negative and total symptoms of the PANSS, which were higher in the Sham group. At the endpoint both groups had a significant decrease from basal score. In the ECT group the PANSS total score decreased 8.78%, from 81.23 to 74.75 (p = 0.042), while the positive subscale had a mean reduction of 19% (19.31 to 16.17, p = 0.006). In the Sham group, the mean reduction of PANSS total score was 15.27% (96.80 to 87.43; p = 0.036), and the PANSS positive subscale decreased 27.81% (22.90 to 19.14, p = 0.008). The CGI score in ECT group decreased 23.0% (5.23 to 4.17; p = 0.001) and decreased 24.31% in the Sham ECT group (5.80 to 4.86; p = 0.004). Discussion In this pilot study, we found no difference between the groups.
Full text:
Available
Index:
LILACS (Americas)
Type of study:
Controlled clinical trial
Language:
English
Journal:
Arch. Clin. Psychiatry (Impr.)
Journal subject:
Psychiatry
Year:
2017
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
University of São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS